Boston—Can treatment of
hepatitis C infection with new direct-acting antivirals (DAAs) be
shortened to less than 12 weeks? Interim results from a recent trial
suggest treatment durations of eight or even four weeks may be possible
with the right combination of drugs.
Shortened regimens would help contain health care costs, with 12-week
courses of new DAAs hovering close to $100,000. Prolonged treatment may
also compromise patient adherence to therapy, experts said.
“Optimized regimens may allow an eight-week duration that may be
broadly applicable across diverse patient groups,” said Eric Lawitz, MD,
vice president of scientific and research development at The Texas
Liver Institute, in San Antonio, who led the study. Dr. Lawitz, also
clinical professor of medicine at the San Antonio University of Texas
Health Science Center, said large randomized trials are needed before
changes to clinical practice can be made.
Labels: DAA's, HCV Drugs in Development, shorter treatments